Robert J. Schmittling

3.2k total citations · 1 hit paper
31 papers, 2.5k citations indexed

About

Robert J. Schmittling is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Robert J. Schmittling has authored 31 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Immunology, 19 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Robert J. Schmittling's work include Immunotherapy and Immune Responses (17 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Immune Cell Function and Interaction (9 papers). Robert J. Schmittling is often cited by papers focused on Immunotherapy and Immune Responses (17 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Immune Cell Function and Interaction (9 papers). Robert J. Schmittling collaborates with scholars based in United States, France and Australia. Robert J. Schmittling's co-authors include John H. Sampson, Roger E. McLendon, Allan H. Friedman, Duane A. Mitchell, James E. Herndon, Gary E. Archer, Darell D. Bigner, Henry S. Friedman, Weihua Xie and Amy B. Heimberger and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Robert J. Schmittling

31 papers receiving 2.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

2010 613 citations John H. Sampson, Amy B. Heimberger et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert J. Schmittling United States	18	1.4k	1.3k	1.0k	570	325	31	2.5k
Elias Sayour United States	25	1000 0.7×	962 0.7×	531 0.5×	657 1.2×	119 0.4×	81	2.0k
Syed R. Husain United States	30	772 0.5×	1.2k 0.9×	437 0.4×	688 1.2×	193 0.6×	54	2.5k
Karim Y. Helmy United States	18	407 0.3×	859 0.7×	727 0.7×	848 1.5×	147 0.5×	20	2.2k
S. Farzana Hussain United States	16	676 0.5×	1.2k 0.9×	453 0.4×	351 0.6×	94 0.3×	19	1.7k
Kendra L. Congdon United States	14	614 0.4×	718 0.5×	417 0.4×	999 1.8×	71 0.2×	25	1.9k
Alessandra Dondero Italy	28	1.2k 0.8×	2.2k 1.7×	180 0.2×	442 0.8×	110 0.3×	42	2.8k
Karen Clise-Dwyer United States	23	781 0.5×	1.1k 0.8×	182 0.2×	795 1.4×	95 0.3×	54	2.2k
Smita K. Nair United States	14	619 0.4×	601 0.5×	292 0.3×	513 0.9×	78 0.2×	39	1.4k
Steven L. Highfill United States	23	1.6k 1.1×	1.7k 1.3×	144 0.1×	719 1.3×	63 0.2×	86	2.9k
Jai Rautela Australia	19	1.0k 0.7×	1.3k 1.0×	148 0.1×	648 1.1×	124 0.4×	31	2.1k

Countries citing papers authored by Robert J. Schmittling

Since Specialization

Citations

This map shows the geographic impact of Robert J. Schmittling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Schmittling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Schmittling more than expected).

Fields of papers citing papers by Robert J. Schmittling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Schmittling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Schmittling. The network helps show where Robert J. Schmittling may publish in the future.

Co-authorship network of co-authors of Robert J. Schmittling

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Schmittling. A scholar is included among the top collaborators of Robert J. Schmittling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Schmittling. Robert J. Schmittling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gedeon, Patrick C., Teilo Schaller, Satish K. Chitneni, et al.. (2018). A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. Clinical Cancer Research. 24(15). 3611–3631. 38 indexed citations

Swartz, Adam M., Elizabeth A. Reap, Pamela K. Norberg, et al.. (2018). A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis. Journal of Immunological Methods. 459. 90–93. 5 indexed citations

Batich, Kristen A., Elizabeth A. Reap, Gary E. Archer, et al.. (2017). Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research. 23(8). 1898–1909. 242 indexed citations

Saraswathula, Anirudh, Elizabeth A. Reap, Bryan D. Choi, et al.. (2016). Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunology Immunotherapy. 65(2). 205–211. 6 indexed citations

Nair, Smita K., Timothy Driscoll, David Boczkowski, et al.. (2015). Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. Journal of Neuro-Oncology. 125(1). 65–74. 26 indexed citations

Nair, Smita K., Gabriel De Leon, David Boczkowski, et al.. (2014). Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells. Clinical Cancer Research. 20(10). 2684–2694. 74 indexed citations

Sampson, John H., Bryan D. Choi, Luis Sánchez-Pérez, et al.. (2013). EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss. Clinical Cancer Research. 20(4). 972–984. 241 indexed citations

Sánchez-Pérez, Luis, Bryan D. Choi, Elizabeth A. Reap, et al.. (2013). BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunology Immunotherapy. 62(6). 983–987. 13 indexed citations

Sánchez-Pérez, Luis, Bryan D. Choi, Gary E. Archer, et al.. (2013). Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice. PLoS ONE. 8(3). e59082–e59082. 52 indexed citations

10.

Sampson, John H., Robert J. Schmittling, Gary E. Archer, et al.. (2012). A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma. PLoS ONE. 7(2). e31046–e31046. 91 indexed citations

11.

Sampson, John H., Amy B. Heimberger, Gary E. Archer, et al.. (2010). Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology. 28(31). 4722–4729. 613 indexed citations breakdown →

12.

Sampson, John H., Kenneth Aldape, Gerald E. Archer, et al.. (2010). Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 13(3). 324–333. 279 indexed citations

13.

Heimberger, Amy B., Gary E. Archer, Duane A. Mitchell, et al.. (2009). Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM. Journal of Clinical Oncology. 27(15_suppl). 2021–2021. 6 indexed citations

14.

Schmittling, Robert J., Gary E. Archer, Duane A. Mitchell, et al.. (2008). Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. Journal of Immunological Methods. 339(1). 74–81. 41 indexed citations

15.

Mitchell, Duane A., Weihua Xie, Robert J. Schmittling, et al.. (2007). Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology. 10(1). 10–18. 311 indexed citations

16.

Learn, Chris A., Peter M. Grossi, Robert J. Schmittling, et al.. (2006). Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity. Journal of Neuroimmunology. 182(1-2). 63–72. 6 indexed citations

17.

Webb, Iain J., Jonathan W. Friedberg, John G. Gribben, et al.. (2002). Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma. Biology of Blood and Marrow Transplantation. 8(8). 429–434. 7 indexed citations

18.

Bolton, Wade E., et al.. (1994). Expression of proliferation‐associated antigens (PCNA, p120, p145) during the reentry of G₀ cells into the cell cycle. Cytometry. 17(1). 66–74. 29 indexed citations

19.

Schmittling, Robert J., Olavi Siiman, Norma S. Kenyon, & Wade E. Bolton. (1993). Depletion of Infiltrating Leukocytes and Identification of Normal Fibroblasts prior to the Proliferative Assessment of Rare Event Tumor Cells. Annals of the New York Academy of Sciences. 677(1). 447–449. 1 indexed citations

20.

Bolton, Wade E., et al.. (1992). Expression of proliferation associated antigens in the cell cycle of synchronized mammalian cells. Cytometry. 13(2). 117–126. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact